Stocks and Investing
Stocks and Investing
Wed, June 7, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ed Arce Maintained (AKRO) at Strong Buy with Increased Target to $64 on, Jun 7th, 2023
Ed Arce of HC Wainwright & Co., Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Increased Target from $62 to $64 on, Jun 7th, 2023.
Ed has made no other calls on AKRO in the last 4 months.
There is 1 other peer that has a rating on AKRO. Out of the 1 peers that are also analyzing AKRO, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $59 on, Wednesday, May 17th, 2023
Contributing Sources